Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 204 participants.
Also called NCT07800572
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 204 participants
- Sponsor
- Registry
-
NCT07800572
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07800572. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-06 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Anisodine Hydrobromide
- Intervention (Drug)
- Anisodine Hydrobromide Placebo
- Lead sponsor
- Capital Medical University
Record details
- Record id
cardio:ct-nct07800572- Content hash
f0c31db81ec4a9e173a4413aa33c18b12518a71bce1358f60bfc98c3a525e83f